Corbus Reports First Patient Dosed in TEMPO-1 and Announces CANYON-1 Data

Corbus Pharmaceuticals dosed the first patient in the TEMPO-1 registrational study for sutantatug envedotin and reported mean weight loss of 5% after 12 weeks in the CANYON-1 obesity study. These milestones highlight significant advancement in both oncology and obesity clinical programs.